Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.

Velcicky J, Mathison CJN, Nikulin V, Pflieger D, Epple R, Azimioara M, Cow C, Michellys PY, Rigollier P, Beisner DR, Bodendorf U, Guerini D, Liu B, Wen B, Zaharevitz S, Brandl T.

ACS Med Chem Lett. 2019 May 23;10(6):887-892. doi: 10.1021/acsmedchemlett.9b00044. eCollection 2019 Jun 13.

PMID:
31223443
2.

Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model.

Sanderlin EJ, Marie M, Velcicky J, Loetscher P, Yang LV.

Eur J Pharmacol. 2019 Jun 5;852:218-230. doi: 10.1016/j.ejphar.2019.03.038. Epub 2019 Mar 28.

PMID:
30930250
3.

Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

Velcicky J, Schlapbach A, Heng R, Revesz L, Pflieger D, Blum E, Hawtin S, Huppertz C, Feifel R, Hersperger R.

ACS Med Chem Lett. 2018 Mar 20;9(4):392-396. doi: 10.1021/acsmedchemlett.8b00098. eCollection 2018 Apr 12.

4.

Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo.

Velcicky J, Bodendorf U, Rigollier P, Epple R, Beisner DR, Guerini D, Smith P, Liu B, Feifel R, Wipfli P, Aichholz R, Couttet P, Dix I, Widmer T, Wen B, Brandl T.

J Med Chem. 2018 Feb 8;61(3):865-880. doi: 10.1021/acs.jmedchem.7b01371. Epub 2018 Jan 23.

PMID:
29359565
5.

Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis.

Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D, Nash M, Loetscher P.

Bioorg Med Chem. 2017 Aug 15;25(16):4512-4525. doi: 10.1016/j.bmc.2017.06.050. Epub 2017 Jun 29.

PMID:
28689977
6.

Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis.

Velcicky J, Miltz W, Oberhauser B, Orain D, Vaupel A, Weigand K, Dawson King J, Littlewood-Evans A, Nash M, Feifel R, Loetscher P.

J Med Chem. 2017 May 11;60(9):3672-3683. doi: 10.1021/acs.jmedchem.6b01703. Epub 2017 Apr 26.

PMID:
28445047
7.

Nucleoside analogues with a 1,3-diene-Fe(CO)3 substructure: stereoselective synthesis, configurational assignment, and apoptosis-inducing activity.

Hirschhäuser C, Velcicky J, Schlawe D, Hessler E, Majdalani A, Neudörfl JM, Prokop A, Wieder T, Schmalz HG.

Chemistry. 2013 Sep 23;19(39):13017-29. doi: 10.1002/chem.201301672. Epub 2013 Aug 9.

PMID:
23934861
8.

Palladium-catalyzed cyanomethylation of aryl halides through domino Suzuki coupling-isoxazole fragmentation.

Velcicky J, Soicke A, Steiner R, Schmalz HG.

J Am Chem Soc. 2011 May 11;133(18):6948-51. doi: 10.1021/ja201743j. Epub 2011 Apr 19.

PMID:
21504197
9.

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.

Revesz L, Schlapbach A, Aichholz R, Feifel R, Hawtin S, Heng R, Hiestand P, Jahnke W, Koch G, Kroemer M, Möbitz H, Scheufler C, Velcicky J, Huppertz C.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4715-8. doi: 10.1016/j.bmcl.2010.04.024. Epub 2010 Apr 13.

PMID:
20594847
10.

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.

Revesz L, Schlapbach A, Aichholz R, Dawson J, Feifel R, Hawtin S, Littlewood-Evans A, Koch G, Kroemer M, Möbitz H, Scheufler C, Velcicky J, Huppertz C.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4719-23. doi: 10.1016/j.bmcl.2010.04.023. Epub 2010 Apr 11.

PMID:
20591669
11.

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.

Velcicky J, Feifel R, Hawtin S, Heng R, Huppertz C, Koch G, Kroemer M, Moebitz H, Revesz L, Scheufler C, Schlapbach A.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1293-7. doi: 10.1016/j.bmcl.2009.10.138. Epub 2009 Nov 3.

PMID:
20060294
12.

Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.

Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, Moebitz H, Revesz L, Scheufler C, Velcicky J, Waelchli R, Huppertz C.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6142-6. doi: 10.1016/j.bmcl.2008.10.039. Epub 2008 Oct 11.

PMID:
18945615
13.

Total synthesis of (-)- and ent-(+)-vindoline and related alkaloids.

Ishikawa H, Elliott GI, Velcicky J, Choi Y, Boger DL.

J Am Chem Soc. 2006 Aug 16;128(32):10596-612.

14.

Total synthesis of (-)- and ent-(+)-vindorosine: tandem intramolecular Diels-Alder/1,3-dipolar cycloaddition of 1,3,4-oxadiazoles.

Elliott GI, Velcicky J, Ishikawa H, Li Y, Boger DL.

Angew Chem Int Ed Engl. 2006 Jan 16;45(4):620-2. No abstract available.

PMID:
16355429
15.

Total synthesis of (-)- and ent-(+)-vindoline.

Choi Y, Ishikawa H, Velcicky J, Elliott GI, Miller MM, Boger DL.

Org Lett. 2005 Sep 29;7(20):4539-42.

16.

Transition-metal-mediated synthesis of novel carbocyclic nucleoside analogues with antitumoral activity.

Velcicky J, Lanver A, Lex J, Prokop A, Wieder T, Schmalz HG.

Chemistry. 2004 Oct 11;10(20):5087-110.

PMID:
15372578
17.

Iron-containing nucleoside analogues with pronounced apoptosis-inducing activity.

Schlawe D, Majdalani A, Velcicky J, Hessler E, Wieder T, Prokop A, Schmalz HG.

Angew Chem Int Ed Engl. 2004 Mar 19;43(13):1731-4. No abstract available.

PMID:
15038051
18.

An efficient organometallic approach to new carbocyclic nucleoside analogues.

Velcicky J, Lex J, Schmalz HG.

Org Lett. 2002 Feb 21;4(4):565-8.

PMID:
11843592

Supplemental Content

Loading ...
Support Center